Teva's Pivot to Growth Is Working-But 35% Brand Growth Has to Keep Outpacing Generic Pressure

Teva's pivot has moved from concept to numbers test

Teva's turnaround is no longer just a strategy pitch. After 11 consecutive quarters of growth and 2025 revenues of $17.3 billion, up 4% year over year in U.S. dollars, the company has shown it can keep expanding. The remaining question is whether innovation can keep improving the portfolio mix faster than generics keep pressuring the top line.

Why the "accelerate" message matters now

Management is no longer asking investors to wait for a future possibility. Teva is arguing that the shift from a generics base toward a more balanced biopharma profile should gather speed. That makes the next few quarters more important than the original pivot announcement.

If that acceleration starts showing up in mix, cash generation, and valuation, the stock has room to reprice. If not, Teva risks staying trapped in the market's older view of the business as mainly a generics player.

Brand growth looks broad enough to matter

The clearest sign that the pivot has substance is the performance of Teva's innovative portfolio. In 2025, its key innovative brands surpassed $3 billion and grew 35% year over year in local currency. Just as important, the growth was not dependent on a single product: AUSTEDO produced $2.26 billion in 2025 revenue, up 34% in LC; AJOVY reached $673 million, up 30% in LC; and UZEDY hit $191 million, up 63% in LC.

UZEDY's traction supports the commercial case

That breadth matters because the story does not rest on one hero asset. UZEDY also stands out because it is not only competing inside an existing category. Teva says UZEDY is the fastest growing long-acting injectable (LAI) and has nearly doubled the overall risperidone market since launch. Whether that translates into lasting mix improvement remains to be seen, but it is a stronger commercial signal than narrow, single-product dependence.

Q1 2026 showed both strengths and limits

The first quarter of 2026 made the current setup clearer. Total revenue was up 2% in U.S. dollars, but down 3% in local currency, as lower lenalidomide sales weighed on the generics segment. At the same time, Teva's key innovative brands grew 41% in local currency, with AUSTEDO, AJOVY, and UZEDY still posting strong numbers.

That is the real scoreboard. The brand story is holding up, but the company still needs those gains to offset uneven performance in generics. After 11 consecutive quarters of growth and another year of expansion in 2025, the question is no longer whether the pivot is believable. It is whether growth can keep compounding through messier quarters.

What would make the thesis stronger from here

Signals to watch

• More quarters where innovative growth is strong enough to offset generic headwinds.
• Evidence that management's "accelerate" message is translating into sustained mix improvement, not just a better narrative.
• Signs that the commercial follow-through is broadening beyond the current core brands.

Watchpoints

• Whether U.S. generic pressure around lenalidomide stays contained or becomes a recurring drag.
• Whether brand mix keeps improving in a visible way, rather than relying mostly on currency effects or timing.
• Whether the growth engine remains diversified instead of becoming dependent on one product again.

What would weaken the case

If quarters like Q1 2026 start to recur without enough innovation-led offset, the rerating case weakens quickly. For now, the thesis is straightforward: more balanced quarters can strengthen the story, while heavier generic erosion can slow it fast.